Rankings
▼
Calendar
ESPR Q1 2021 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ESPR
Esperion Therapeutics, Inc.
$577M
Q1 2021 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$8M
+333.6% YoY
Gross Profit
$6M
77.6% margin
Operating Income
-$83M
-1038.2% margin
Net Income
-$91M
-1139.8% margin
EPS (Diluted)
$-3.50
QoQ Revenue Growth
-17.2%
Cash Flow
Operating Cash Flow
-$89M
Free Cash Flow
-$89M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$279M
Total Liabilities
$548M
Stockholders' Equity
-$269M
Cash & Equivalents
$218M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$2M
+333.6%
Gross Profit
$6M
$2M
+242.4%
Operating Income
-$83M
-$74M
-11.3%
Net Income
-$91M
-$78M
-16.2%
Revenue Segments
Collaboration Revenue
$2M
50%
Product Sales Bulk Tablets Nilemdo And Nustendi
$2M
50%
← FY 2021
All Quarters
Q2 2021 →